1103 related articles for article (PubMed ID: 24550347)
1. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
Providência R; Marijon E; Albenque JP; Combes S; Combes N; Jourda F; Hireche H; Morais J; Boveda S
Europace; 2014 Aug; 16(8):1137-44. PubMed ID: 24550347
[TBL] [Abstract][Full Text] [Related]
2. Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations.
Kosiuk J; Koutalas E; Doering M; Sommer P; Rolf S; Breithardt OA; Nedios S; Dinov B; Hindricks G; Richter S; Bollmann A
Europace; 2014 Jul; 16(7):1028-32. PubMed ID: 24489073
[TBL] [Abstract][Full Text] [Related]
3. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
Armbruster HL; Lindsley JP; Moranville MP; Habibi M; Khurram IM; Spragg DD; Berger RD; Calkins H; Marine JE
Ann Pharmacother; 2015 Mar; 49(3):278-84. PubMed ID: 25515868
[TBL] [Abstract][Full Text] [Related]
4. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
Abraham NS; Singh S; Alexander GC; Heien H; Haas LR; Crown W; Shah ND
BMJ; 2015 Apr; 350():h1857. PubMed ID: 25910928
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation].
Gorzelak-Pabiś P; Duraj I; Szlagowska L; Ciastkowska A; Broncel M
Pol Merkur Lekarski; 2014 Nov; 37(221):261-4. PubMed ID: 25546985
[TBL] [Abstract][Full Text] [Related]
6. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
7. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
[TBL] [Abstract][Full Text] [Related]
8. Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter.
Yadlapati A; Groh C; Passman R
Am J Cardiol; 2014 Apr; 113(8):1362-3. PubMed ID: 24576547
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation.
Aryal MR; Ukaigwe A; Pandit A; Karmacharya P; Pradhan R; Mainali NR; Pathak R; Jalota L; Bhandari Y; Donato A
Am J Cardiol; 2014 Aug; 114(4):577-82. PubMed ID: 24998087
[TBL] [Abstract][Full Text] [Related]
10. Safety of continuous periprocedural rivaroxaban for patients undergoing left atrial catheter ablation procedures.
Dillier R; Ammar S; Hessling G; Kaess B; Pavaci H; Buiatti A; Semmler V; Kathan S; Hofmann M; Lennerz C; Kolb C; Reents T; Deisenhofer I
Circ Arrhythm Electrophysiol; 2014 Aug; 7(4):576-82. PubMed ID: 24970293
[TBL] [Abstract][Full Text] [Related]
11. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.
Lakkireddy D; Reddy YM; Di Biase L; Vallakati A; Mansour MC; Santangeli P; Gangireddy S; Swarup V; Chalhoub F; Atkins D; Bommana S; Verma A; Sanchez JE; Burkhardt JD; Barrett CD; Baheiry S; Ruskin J; Reddy V; Natale A
J Am Coll Cardiol; 2014 Mar; 63(10):982-8. PubMed ID: 24412445
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Skjøth F; Larsen TB; Rasmussen LH; Lip GY
Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Trends of Inpatient Hospitalisation for Significant Haemorrhage in Patients Anticoagulated for Atrial Fibrillation before and after the Release of Novel Anticoagulants.
Badal M; Aryal MR; Mege J; Chaudhary A; Donato AA
Heart Lung Circ; 2015 Jan; 24(1):94-7. PubMed ID: 25108758
[TBL] [Abstract][Full Text] [Related]
14. Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban.
Winkle RA; Mead RH; Engel G; Kong MH; Patrawala RA
Europace; 2014 Oct; 16(10):1443-9. PubMed ID: 25115168
[TBL] [Abstract][Full Text] [Related]
15. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
16. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS
Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161
[TBL] [Abstract][Full Text] [Related]
17. A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation.
Snipelisky D; Ray JC; Ung R; Duart M; Kauffman C; Kusumoto F
J Interv Card Electrophysiol; 2014 Dec; 41(3):231-6. PubMed ID: 25380703
[TBL] [Abstract][Full Text] [Related]
18. Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation.
Stepanyan G; Badhwar N; Lee RJ; Marcus GM; Lee BK; Tseng ZH; Vedantham V; Olgin J; Scheinman M; Gerstenfeld EP
J Interv Card Electrophysiol; 2014 Jun; 40(1):33-8. PubMed ID: 24643666
[TBL] [Abstract][Full Text] [Related]
19. Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation.
Eitel C; Koch J; Sommer P; John S; Kircher S; Bollmann A; Arya A; Piorkowski C; Hindricks G
Europace; 2013 Nov; 15(11):1587-93. PubMed ID: 23703362
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation.
Nairooz R; Sardar P; Pino M; Aronow WS; Sewani A; Mukherjee D; Paydak H; Maskoun W
Int J Cardiol; 2015; 187():345-53. PubMed ID: 25839640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]